Table 1.

Baseline patient and disease characteristics in carfilzomib-treated patients reporting a cardiac or vascular-related adverse event

	Patients N = 12
Age, median years (range)	59 (49–77)
Male sex, %	50
Durie-Salmon stage at diagnosis
IA	3
IIA	1
IIIA	7
IIIB	1
ISS stage at diagnosis
I	0
II	3
III	3
Unknown	6
Lines of previous anti-MM therapy, median	5
Prior bortezomib, n (%)	11 (92)
Prior autologous stem cell transplant, n (%)	9 (75)
Prior anthracycline, n (%)	3 (25)

ISS, International Staging System; MM, multiple myeloma.